Lasset C - Search Results

1

Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma.

Combaret V, Gross N, Lasset C, Frappaz D, Beretta-Brognara C, Philip T, Beck D, Favrot MC. Combaret V, et al. Among authors: lasset c. Eur J Cancer. 1997 Oct;33(12):2101-5. doi: 10.1016/s0959-8049(97)00236-0. Eur J Cancer. 1997. PMID: 9516862

2

Treatment duration before bone marrow transplantation in stage IV neuroblastoma. European Bone Marrow Transplant Group Solid Tumour Registry.

Ladenstein R, Lasset C, Philip T. Ladenstein R, et al. Among authors: lasset c. Lancet. 1992 Oct 10;340(8824):916-7. doi: 10.1016/0140-6736(92)93333-i. Lancet. 1992. PMID: 1357330 No abstract available.

3

Documentation of the EBMT solid tumor registry (STR) data. A "crux (? or X) for doctors"?

Ladenstein R, Chauvin F, Abdelbost Z, Lasset C, Garaventa A, Philip T. Ladenstein R, et al. Among authors: lasset c. Bone Marrow Transplant. 1991;7 Suppl 2:137. Bone Marrow Transplant. 1991. PMID: 1878681 No abstract available.

4

European Bone Marrow Registry in solid tumors: 7 years of experience.

Chauvin F, Ladenstein R, Lasset C, Pinzani V, Abdelbost Z, Bartolomucci A, Philip T. Chauvin F, et al. Among authors: lasset c. Bone Marrow Transplant. 1991;7 Suppl 2:157. Bone Marrow Transplant. 1991. PMID: 1878691 No abstract available.

5

A single center experience with bone marrow transplantation for high risk neuroblastoma.

Ladenstein R, Lasset C, Bouffet E, Brunat-Mentigny M, Biron P, Philip I, Chauvin F, Philip T. Ladenstein R, et al. Among authors: lasset c. Bone Marrow Transplant. 1991;7 Suppl 2:93. Bone Marrow Transplant. 1991. PMID: 1878741 Clinical Trial. No abstract available.

6

High-dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma.

Philip T, Hartmann O, Biron P, Cahn JY, Pein F, Bordigoni P, Souillet G, Gartner M, Lasset C, Chauvin F. Philip T, et al. Among authors: lasset c. J Clin Oncol. 1988 Jul;6(7):1118-24. doi: 10.1200/JCO.1988.6.7.1118. J Clin Oncol. 1988. PMID: 3292712

7

[Systematic screening for neuroblastoma].

Frappaz D, Philip T, Chauvin F, Mathieu P, Lasset C, Estève J, Brunat-Mentigny M. Frappaz D, et al. Among authors: lasset c. Arch Pediatr. 1995 Oct;2(10):1016-8. doi: 10.1016/0929-693x(96)89902-7. Arch Pediatr. 1995. PMID: 7496460 French. No abstract available.

8

CD44--a new prognostic marker for neuroblastoma.

Favrot MC, Combaret V, Lasset C. Favrot MC, et al. Among authors: lasset c. N Engl J Med. 1993 Dec 23;329(26):1965. doi: 10.1056/NEJM199312233292615. N Engl J Med. 1993. PMID: 7504209 No abstract available.

9

Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors.

Combaret V, Lasset C, Frappaz D, Bouvier R, Thiesse P, Rebillard AC, Philip T, Favrot MC. Combaret V, et al. Among authors: lasset c. Eur J Cancer. 1995;31A(4):545-9. doi: 10.1016/0959-8049(95)00027-g. Eur J Cancer. 1995. PMID: 7576964

10

Is neuroblastoma screening evaluation needed and feasible?

Estève J, Parker L, Roy P, Herrmann F, Duffy S, Frappaz D, Lasset C, Hill C, Sancho-Garnier H, Michaelis J, et al. Estève J, et al. Among authors: lasset c. Br J Cancer. 1995 Jun;71(6):1125-31. doi: 10.1038/bjc.1995.219. Br J Cancer. 1995. PMID: 7779698 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

224 results

Search Page

Filters